The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes

Pediatric Research

Volumn 62, Issue 6, 2007, Pages 746-749

  Rodriguez, Luisa M ^a   Mason, Kimberly J ^a   Haymond, Morey W ^a   Heptulla, Rubina A ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTAME; GLUCAGON; GLUCOSE; INSULIN; INSULIN LISPRO; PARACETAMOL; PRAMLINTIDE;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG INFUSION; DRUG SAFETY; FEMALE; FOOD INTAKE; GLUCAGON BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NAUSEA; POSTPRANDIAL STATE; PRIORITY JOURNAL; RISK ASSESSMENT; STOMACH EMPTYING; VOMITING;

ADOLESCENT; AMYLOID; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GASTRIC EMPTYING; GLUCAGON; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INFUSIONS, PARENTERAL; INJECTIONS, SUBCUTANEOUS; INSULIN; MALE; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 36348963013     PISSN: 00313998     EISSN: None     Source Type: Journal    
DOI: 10.1203/PDR.0b013e318159af8c     Document Type: Article

References (22)

1. Gedulin BR, Rink TJ, Young AA 1997 Dose-response for glucagonostatic effect of amylin in rats. Metabolism 46:67-70
2. Moore CX, Cooper GJ 1991 Co-secretion of amylin and insulin from cultured islet beta-cells: modulation by nutrient secretagogues, islet hormones and hypoglycemic agents. Biochem Biophys Res Commun 179:1-9
3. Koda JE, Fineman M, Rink TJ, Dailey GE, Muchmore DB, Linarelli LG 1992 Amylin concentrations and glucose control. Lancet 339:1179-1180
4. Thompson RG, Peterson J, Gottlieb A, Mullane J 1997 Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial. Diabetes 46:632-636
5. Samsom M, Szarka LA, Camilleri M, Vella A, Zinsmeister AR, Rizza RA 2000 Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition. Am J Physiol Gastrointest Liver Physiol 278:G946-G951
6. Kong MF, King P, Macdonald IA, Blackshaw PE, Perkins AC, Armstrong E, Buchanan KD, Tattersall RB 1998 Effect of euglycaemic hyperinsulinaemia on gastric emptying and gastrointestinal hormone responses in normal subjects. Diabetologia 41:474-481
7. Nyholm B, Orskov L, Hove KY, Gravholt CH, Moller N, Alberti KG, Moyses C, Kolterman O, Schmitz O 1999 The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus. Metabolism 48:935-941
8. Fineman M, Weyer C, Maggs DG, Strobel S, Kolterman OG 2002 The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. Horm Metab Res 34:504-508
9. Heptulla RA, Rodriguez LM, Bomgaars L, Haymond MW 2005 The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes. Diabetes 54:1100-1107
10. Kong MF, Stubbs TA, King P, Macdonald IA, Lambourne JE, Blackshaw PE, Perkins AC, Tattersall RB 1998 The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM. Diabetologia 41:577-583
11. Percy AJ, Trainor DA, Rittenhouse J, Phelps J, Koda JE 1996 Development of sensitive immunoassays to detect amylin and amylin-like peptides in unextracted plasma. Clin Chem 42:576-585
12. Lewanczuk RZ, Paty BW, Toth EL 2004 Comparison of the [13C]glucose breath test to the hyperinsulinemic-euglycemic clamp when determining insulin resistance. Diabetes Care 27:441-447
13. Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, Maggs DG, Weyer C, Kolterman OG 2002 A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 25:724-730
14. Maggs DG, Fineman M, Kornstein J, Burrell T, Schwartz S, Wang Y, Ruggles JA, Kolterman OG, Weyer C 2004 Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study. Diabetes Metab Res Rev 20:55-60
15. Rabasa-Lhoret R, Burelle Y, Ducros F, Bourque J, Lavoie C, Massicotte D, Peronnet F, Chiasson JL 2001 Use of an alpha-glucosidase inhibitor to maintain glucose homoeostasis during postprandial exercise in intensively treated Type 1 diabetic subjects. Diabet Med 18:739-744
16. Fujisawa T, Ikegami H, Inoue K, Kawabata Y, Ogihara T 2005 Effect of two alpha-glucosidase inhibitors, voglibose and acarbose, on postprandial hyperglycemia correlates with subjective abdominal symptoms. Metabolism 54:387-390
17. Weyer C, Gottlieb A, Kim DD, Lutz K, Schwartz S, Gutierrez M, Wang Y, Ruggles JA, Kolterman OG, Maggs DG 2003 Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study. Diabetes Care 26:3074-3079
18. Monsod TP, Tamborlane WV, Coraluzzi L, Bronson M, Yong-Zhan T, Ahern JA 2001 Epipen as an alternative to glucagon in the treatment of hypoglycemia in children with diabetes. Diabetes Care 24:701-704
19. Haymond MW, Schreiner B 2001 Mini-dose glucagon rescue for hypoglycemia in children with type 1 diabetes. Diabetes Care 24:643-645
20. Stenninger E, Aman J 1993 Intranasal glucagon treatment relieves hypoglycaemia in children with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 36:931-935
21. Fineman MS, Koda JE, Shen LZ, Strobel SA, Maggs DG, Weyer C, Kolterman OG 2002 The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism 51:636-641
22. Kolterman OG, Schwartz S, Corder C, Levy B, Klaff L, Peterson J, Gottlieb A 1996 Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Diabetologia 39:492-499